Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O4XW
|
|||
| Former ID |
DCL000190
|
|||
| Drug Name |
ONO-4819
|
|||
| Synonyms |
Rivenprost; AE1-734; ONO-4819CD; ONO-4819.CD; ONO-AE1-734
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Fracture [ICD-11: ND56; ICD-10: T14.2] | Discontinued in Phase 2 | [1], [2] | |
| Company |
Novartis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H34O6S
|
|||
| Canonical SMILES |
COCC1=CC=CC(=C1)CC(C=CC2C(CC(=O)C2CCSCCCC(=O)OC)O)O
|
|||
| InChI |
1S/C24H34O6S/c1-29-16-18-6-3-5-17(13-18)14-19(25)8-9-20-21(23(27)15-22(20)26)10-12-31-11-4-7-24(28)30-2/h3,5-6,8-9,13,19-22,25-26H,4,7,10-12,14-16H2,1-2H3/b9-8+/t19-,20-,21-,22-/m1/s1
|
|||
| InChIKey |
FBQUXLIJKPWCAO-AZIFJQEOSA-N
|
|||
| CAS Number |
CAS 256382-08-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin E2 receptor EP4 (PTGER4) | Target Info | Agonist | [3], [4], [5] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| Renin secretion | ||||
| Pathways in cancer | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| IL4 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Vitamin D Receptor Pathway | ||||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1930). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016907) | |||
| REF 3 | Effect of a prostaglandin EP4 receptor agonist on early fixation of hydroxyapatite/titanium composite- and titanium-coated rough-surfaced implants ... J Biomed Mater Res A. 2010 Mar 1;92(3):1202-9. | |||
| REF 4 | Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone. 2007 Oct;41(4):543-8. | |||
| REF 5 | Effects on improvement of blood flow in the chronically compressed cauda equina: comparison between a selective prostaglandin E receptor (EP4) agonist and a prostaglandin E1 derivate. Spine (Phila Pa1976). 2006 Apr 15;31(8):869-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.